OrthoPediatrics Corp 2025年度报告

FORM 10-K [Mark One] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December31, 2025OR☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number 001-38242 ORTHOPEDIATRICS CORP. (Exact name of registrant as specified in its charter) Delaware26-1761833(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification Number) 2850 Frontier DriveWarsaw, Indiana46582(Address of principal executive offices)(Zip Code) Registrant’s telephone number, including area code: (574) 268-6379 Securities registered pursuant to Section 12(b) of the Act:Title of Each ClassTrading Symbol(s)Name of each exchange on which registeredCommon Stock, $0.00025 par value per shareKIDSNasdaq Global Market Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YesNo☒ Indicate by check mark whether the registrant(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filingrequirements for the past 90 days. Yes☒No Indicate by check mark whether the registrant has submitted electronically every interactive data file required to be submitted pursuant to Rule 405 ofRegulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)Yes☒No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or anemerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growthcompany” in Rule 12b-2 of the Exchange Act. Large accelerated filerAccelerated filer☒Non-accelerated filerSmaller Reporting CompanyEmerging Growth Company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any newor revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internalcontrol over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report☒ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in thefiling reflect the correction of an error to previously issued financial statements. Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensationreceived by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b). Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).Yes☐No☒ The aggregate market value of the registrant's common stock held by non-affiliates of the registrant was approximately $362.5 million as of the lastbusiness day of the registrant's most recently completed second fiscal quarter (June 30, 2025), based upon the closing sale price for the registrant'scommon stock on that day as reported by the Nasdaq Global Market. Shares of common stock held by each officer and director of the registrant and by each person who owns 10 percent or more of outstanding common stock on June 30, 2025 have been excluded in that such persons may be deemedto be affiliates. This determination of affiliate status is not necessarily conclusive for other purposes. As of February 28, 2026, the registrant had 25,278,787 outstanding shares of common stock, $0.00025 par value per share. DOCUMENTS INCORPORATED BY REFERENCE Portions of the registrant’s definitive proxy statement for its 2026 Annual Meeting of Stockholders are incorporated by reference into Part III of this Form10-K.2 Statement Regarding Forward-Looking Statements6Risk Factor Summary7PART IItem 1.Business8Item 1A.Risk Factors32Item 1B.Unresolved Staff Comments72Item 1C.Cybersecurity72Item 2.Properties72Item 3.Legal Proceedings73Item 4.Mine Safety Disclosures73PART IIItem 5.Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of EquitySecurities74Item 6.[Reserved]75Item 7.Management's Discussion and Analysis of Financial Condition and Results of Operations76Item 7A.Quantitative and Qualitative Disclosure about Market Risk87Item 8.Financia